CN110799207B - 缺少C5结合的Coversin变体 - Google Patents

缺少C5结合的Coversin变体 Download PDF

Info

Publication number
CN110799207B
CN110799207B CN201880040770.5A CN201880040770A CN110799207B CN 110799207 B CN110799207 B CN 110799207B CN 201880040770 A CN201880040770 A CN 201880040770A CN 110799207 B CN110799207 B CN 110799207B
Authority
CN
China
Prior art keywords
seq
coversin
modified
polypeptide
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880040770.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110799207A (zh
Inventor
迈尔斯·安德鲁·纳恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CN110799207A publication Critical patent/CN110799207A/zh
Application granted granted Critical
Publication of CN110799207B publication Critical patent/CN110799207B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880040770.5A 2017-04-21 2018-04-20 缺少C5结合的Coversin变体 Active CN110799207B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
PCT/EP2018/060240 WO2018193121A1 (en) 2017-04-21 2018-04-20 Coversin variants lacking c5 binding

Publications (2)

Publication Number Publication Date
CN110799207A CN110799207A (zh) 2020-02-14
CN110799207B true CN110799207B (zh) 2024-05-03

Family

ID=58795719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040770.5A Active CN110799207B (zh) 2017-04-21 2018-04-20 缺少C5结合的Coversin变体

Country Status (12)

Country Link
US (2) US11214602B2 (enExample)
EP (1) EP3612207B1 (enExample)
JP (1) JP7183180B2 (enExample)
KR (1) KR102630702B1 (enExample)
CN (1) CN110799207B (enExample)
AU (1) AU2018253961B2 (enExample)
CA (1) CA3060336A1 (enExample)
ES (1) ES2980279T3 (enExample)
GB (1) GB201706406D0 (enExample)
IL (1) IL269856B2 (enExample)
PL (1) PL3612207T3 (enExample)
WO (1) WO2018193121A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098454A2 (en) * 2008-02-05 2009-08-13 Natural Environment Research Council Treatment of diseases and conditions mediated by eicosanoids
WO2010100396A1 (en) * 2009-02-05 2010-09-10 Natural Environment Research Council Modified omci as a complement inhibitor
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077709A1 (en) * 2000-03-21 2003-04-24 Masazumi Kamohara Novel leukotriene B4 receptor
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
CA2840270C (en) 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009098454A2 (en) * 2008-02-05 2009-08-13 Natural Environment Research Council Treatment of diseases and conditions mediated by eicosanoids
CN102066412A (zh) * 2008-02-05 2011-05-18 自然环境研究会 由类二十烷酸介导的疾病和病症的治疗
WO2010100396A1 (en) * 2009-02-05 2010-09-10 Natural Environment Research Council Modified omci as a complement inhibitor
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Function, mechanism and evolution of the moubatin-clade of soft tick lipocalins;MANS B J 等;《Insect Biochemistry and Molecular Biology》;第38卷(第9期);第841-852页 *

Also Published As

Publication number Publication date
IL269856B2 (en) 2024-09-01
CN110799207A (zh) 2020-02-14
EP3612207C0 (en) 2024-04-10
PL3612207T3 (pl) 2024-09-23
GB201706406D0 (en) 2017-06-07
US11214602B2 (en) 2022-01-04
EP3612207B1 (en) 2024-04-10
EP3612207A1 (en) 2020-02-26
WO2018193121A1 (en) 2018-10-25
IL269856A (en) 2019-11-28
AU2018253961A1 (en) 2019-10-31
IL269856B1 (en) 2024-05-01
US20230002456A1 (en) 2023-01-05
JP2020517260A (ja) 2020-06-18
KR20190141163A (ko) 2019-12-23
US20200385434A1 (en) 2020-12-10
ES2980279T3 (es) 2024-09-30
JP7183180B2 (ja) 2022-12-05
KR102630702B1 (ko) 2024-01-29
CA3060336A1 (en) 2018-10-25
AU2018253961B2 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
AU2018253961B2 (en) Coversin variants lacking C5 binding
EP3047024B1 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
AU2009211257A1 (en) Treatment of diseases and conditions mediated by eicosanoids
KR20140054009A (ko) 릴랙신 융합 폴리펩타이드 및 그의 용도
KR20140039257A (ko) 릴랙신을 방출하는 융합 단백질 및 이의 용도
KR20140129163A (ko) 인간 보체 c5에 결합하는 폴리펩티드
JP7621728B2 (ja) プロテアーゼ活性化受容体２のモジュレーター
FR2972006A1 (fr) Nouveaux fragments d'il-33 superactifs et leurs utilisations
DK2393831T3 (en) MODIFIED OMCI AS COMPLEMENT INHIBITOR
JP2025511929A (ja) 長時間作用型顆粒球マクロファージコロニー刺激因子
AU730738B2 (en) Antimicrobially active polypeptides
EP1590458A2 (en) Bradykinin b2 receptor antagonist peptide from amphibian skin
KR20220137876A (ko) 조직 재생의 촉진에 유용한 hmgb1과 관련된 폴리펩티드, 이를 포함하는 조성물, 및 이들의 용도
BR112019019819A2 (pt) polipeptídeo de ligação a il-1r-i
CN108866068A (zh) 芋螺毒素GeXXVIIA的基因、多肽及其应用
EP3419994B1 (en) Peptide inhibitors of calcium channels
TW202304957A (zh) Kv1.3阻斷劑
WO2013156771A1 (en) Anti-atherogenic peptides
CN100480264C (zh) 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
CN103059110A (zh) 白念珠菌细胞凋亡促进因子基因及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380704